Trans Fatty Acids and Coronary Heart Disease

Abstract

Epidemiologic evidence has linked trans fatty acids (TFAs) in the diet to coronary heart disease in human populations. It has been estimated that dietary TFAs from partially hydrogenated oils may be responsible for between 30,000 and 100,000 premature coronary deaths per year in the United States. Although it is known that TFAs increase low-density lipoprotein (LDL) cholesterol levels and decrease high-density lipoprotein (HDL) cholesterol levels (markers of coronary heart disease), there is little known about the mechanisms by which TFAs actually function at the cellular level. It is unknown what levels of TFAs are clinically significant and it is unclear how TFAs are associated with cardiac arrhythmias or sudden cardiac death. We hypothesize that TFAs affect membrane structure, thus altering enzymatic pathways that may subsequently induce cardiac arrhythmias and sudden death.

Get full access to this article

View all access options for this article.

References

Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. Harvard School Public Health. 2004 : 1–8.

Emken EA. Nutrition and biochemistry of trans and positional fatty acid isomers in hydrogenated oils. Annu Rev Nutr. 1994 ;4:339– 376.

Lichtenstein AH. Dietary trans fatty acid. J Cardiopulm Rehabil. 2000;20:143– 146.

Craig-Schmidt MC. Worldwide consumption of trans-fatty acids. In: Sebedio JL, Christie WW, eds. Trans Fatty Acids in Human Nutrition. Dundee, Scotland: Oily Press; 1998:50– 113.

NA. Trans fatty acids and coronary heart disease risk. Report of the expert panel on trans fatty acids and coronary heart disease. Am J Clin Nutr. 1995 ;62:655S– 708S.

Enig MG, Atal S, Keeney M, Sampugna J. Isomeric trans fatty acids in the U.S. diet. J Am Coll Nutr. 1990 ;9:471– 486.

Craig-Schmidt MC. World-wide consumption of trans fatty acids. Program from the First International Symposium on Trans Fatty Acids and Health, Copenhagen, Denmark, September 2005 : 4.

Kromhout D, Menotti A, Bloemberg B, et al. Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: the Seven Countries Study. Prev Med. 1995 ;24:308– 315.

Ascherio A, Rimm EB, Giovannucci EL, Spiegelman D, Stampfer M, Willett WC. Dietary fat and risk of coronary heart disease in men: cohort follow-up study in the United States. BMJ. 1996 ;313:84– 90.

10.

Pietinen P, Ascherio A, Korhonen P, et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol. 1997;145:876– 887.

11.

Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997 ;337:1491– 1499.

12.

Lemaitre RN, King IB, Raghunathan TE, et al. Cell membrane trans-fatty acids and the risk of primary cardiac arrest. Circulation. 2002 ;105:697– 701.

13.

Roberts TL, Wood DA, Riemersma RA, Gallagher PJ, Lampe FC. Trans isomers of oleic and linoleic acids in adipose tissue and sudden cardiac death. Lancet. 1995 ;345:278– 282.

14.

Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med. 1999 ;340:1933– 1940.

15.

Judd JT, Clevidence BA, Muesing RA, Wittes J, Sunkin ME, Podczasy JJ. Dietary trans fatty acids: effects on plasma lipids and lipoproteins of healthy men and women. Am J Clin Nutr. 1994 ;59:861– 868.

16.

Almendingen K, Jordal O, Kierulf P, Sandstad B, Pedersen JI. Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil, and butter on serum lipoproteins and Lp[a] in men. J Lipid Res. 1995;36:1370– 1384.

17.

Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990 ;323:439– 445.

18.

Aro A, Jauhiainen M, Partanen R, Salminen I, Mutanen M. Stearic acid, trans fatty acids, and dairy fat: effects on serum and lipoprotein lipids, apolipoproteins, lipoprotein(a), and lipid transfer proteins in healthy subjects. Am J Clin Nutr. 1997 ;65:1419– 1426.

19.

Lemaitre RN, King IB, Mozaffarian D, Sootodehnia D, Siscovick DS. Trans-fatty acids and sudden cardiac death. Program from the First International Symposium on Trans Fatty Acids and Health, Copenhagen, Denmark, September 2005:6 .

20.

Stender S, Dyerberg J, Holmer G, Ovesen L, Sandstrom B. The influence of trans fatty acids on health: a report from the Danish Nutrition Council. Clin Sci. 1995 ;88:375– 392.

21.

Clifton PM, Keogh JB, Noakes M. Trans fatty acids in adipose tissue and the food supply are associated with myocardial infarction. J Nutr. 2004;134:874– 879.

22.

Ibrahim SA, Ghafoorunissa SA. Influence of dietary partially hydrogenated fat high in trans fatty acids on lipid composition and function of intestinal brush border membrane in rats. J Nutr Biochem. 2001;12:116– 120.

23.

Slattery ML, Benson J, Ma KN, Schaffer D, Potter JD. Trans-fatty acids and colon cancer. Nutr Cancer. 2001 ;39:170– 175.

24.

Kummerow FA, Zhou Q, Mahfouz MM. Effect of trans fatty acids on calcium influx into human arterial endothelial cells. Am J Clin Nutr. 1999;70:832– 838.

25.

Sargis RM, Subbaiah PV. Trans unsaturated fatty acids are less oxidizable than cis unsaturated fatty acids and protect endogenous lipids from oxidation in lipoproteins and lipid bilayers. Biochemistry. 2003 ;42:11533– 11543.

26.

Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC. Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr. 2004;80:1521– 1525.

27.

Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr. 2005 ;135:562– 566.

28.

Denke MA. Serum lipid concentrations in humans: trans fatty acids and coronary heart disease risk. Am J Clin Nutr. 1995 ;62:693S– 700S.

29.

Cuchel M, Schwab US, Jones PJH. Impact of hydrogenated fat consumption on endogenous cholesterol synthesis and susceptibility of low density lipoprotein to oxidation in moderately hypercholesterolemic individuals. Metabolism. 1996 ;45:241– 247.

30.

Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem. 2000 ;275:17221– 17224.

31.

Emken EA, Rohwedder WK, Dutton HJ, Dejarlais WJ, Adlof RO. Incorporation of deuterium-labeled cis- and trans-9-octadecenoic acids in humans: plasma, erythrocyte and platelet phospholipids. Lipids. 1979;14:547– 554.

32.

Larque E, Garcia-Ruiz PA, Perez-Llamas F, Zamora S, Gil A. Dietary trans fatty acids alter the composition of microsomes and mitochondria and the activities of microsome Δ6-fatty acid desaturase and glucose-6-phosphatase in livers of pregnant rats. J Nutr. 2003;133:2526– 2531.

33.

Roach C, Feller SE, Ward JA, Shaikh SR, Zerouga M, Stillwell W. Comparison of cis-and trans-fatty acid-containing phosphatidylcholines on membrane properties. Biochemistry. 2004 ;43:6344– 6351.

34.

Woldseth B, Retterstol K, Christophersen BO. Monounsaturated trans fatty acids, elaidic acid and trans-vaccenic acid, metabolism and incorporation in phospholipid molecular species in hepatocytes. Scand J Clin Lab Invest. 1998 ;58:635– 645.

35.

Wolff RL, Entressangles B. Steady-state fluorescence polarization study of structurally defined phospholipids from liver mitochondria of rats fed elaidic acid. Biochim Biophys Acta. 1994 ;1211:198– 200.

36.

Glaser M. Lipid domains in biological membranes. Curr Opin Struct Biol. 1993;3:475– 481.

37.

Edidin M. Patches and fences: probing for plasma membrane domains. J Cell Sci Suppl. 1993 ;17:165– 169.

38.

Mouritsen OG, Jorgensen K. Small-scale lipid-membrane structure: simulation versus experiment. Curr Opin Struct Biol. 1997 ;7:518– 527.

39.

Thompson TE, Tillack TW. Organization of glycosphingolipids in bilayers and plasma membranes of mammalian cells. Annu Rev Biophys Biophys Chem. 1985;14:361– 386.

40.

Schroeder F, Jefferson JR, Kier AB, et al. Membrane cholesterol dynamics: cholesterol domains and kinetic pools. Proc Soc Exp Biol Med. 1991;196:235– 252.

41.

Brown DA, London E. Structure and origin of ordered lipid domains in biological membranes. J Membr Biol. 1998 ;164:103– 114.

42.

London E, Brown DA. Insolubility of lipids in Triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta. 2000 ;1508:182– 195.

43.

Hui S. The spatial distribution of cholesterol in membranes. In: Yeagle PL, ed. The Biology of Cholesterol. Boca Raton, FL: CRC Press; 1988:213– 232.

44.

Schroeder F, Nemecz G. Transmembrane cholesterol distribution. In: Esfahani M, Swaney J, eds. Advances in Cholesterol Research. West Caldwell, NJ: Telford Press; 1990:47– 87.

45.

Brown DA, London E. Structure of detergent-resistant membrane domains: does phase separation occur in biological membranes? Biochem Biophys Res Commun. 1997 ;240:1– 7.

46.

Brown DA, Rose JK. Sorting of GPI-anchored proteins to glyco-lipid-enriched membrane subdomains during transport to the apical cell surface. Cell. 1992 ;68:533– 544.

47.

Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 ;324:781– 788.

48.

Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: the SWORD Investigators: Survival With Oral d-Sotalol. Lancet. 1996 ;348:7– 12.

49.

Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999 ;341:857– 864.

50.

Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT: European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997 ;349:667– 674.

51.

Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: multicenter automatic defibrillator implantation trial investigators. N Engl J Med. 1996 ;335:1933– 1940.

52.

A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997 ;337:1576– 1583.

53.

Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976 ;200:69– 73.

54.

Kromann N, Green A. Epidemiological studies in the Upernavik District, Greenland: incidence of some chronic diseases 1950–1974. Acta Med Scand. 1980 ;208:401– 406.

55.

Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998 ;279:23– 28.

56.

Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336:1046– 1053.

57.

Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. Circulation. 1996 ;94:2337– 2340.

58.

Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002 ;106:2747– 2757.

59.

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione Trial: Gruppo Italiano per lo Studio della Soprav-vivenza nell'Infarto miocardico. Lancet. 1999;354:447– 455.

60.

Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989 ;2:757– 761.

61.

Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian Experiment of Infarct Survival–4. Cardiovasc Drugs Ther. 1997 ;11:485– 491.

62.

de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1995 ;343:1454– 1459.

63.

Zaloga GP, Ruzmetov N, Harvey KA, et al. Omega-3 long chain polyunsaturated fatty acids improve survival following myocardial infarction in rats. J Nutr. 2006 ;136:1874– 1878.

64.

Gao T, Yatani A, Dell'Acqua ML, et al. cAMP-dependent regulation of cardiac L-type Ca²⁺ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron. 1997 ;19:185– 196.

65.

Hain J, Onoue H, Mayrleitner M, Fleischer S, Schindler H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J Biol Chem. 1995;270:2074– 2081.

66.

Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med. 1995 ;123:358– 367.

67.

Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM, Malik AB. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest. 1990 ;85:1991– 1998.

68.

Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997;100:115– 126.

69.

Naruse K, King GL. Protein kinase C and myocardial biology and function. Circ Res. 2000 ;86:1104– 1106.

70.

Sugden PH, Bogoyevitch MA. Intracellular signalling through protein kinases in the heart. Cardiovasc Res. 1995 ;30:478– 492.

71.

Karns LR, Kariya K, Simpson PC. M-CAT, CArG, and Sp1 elements are required for alpha 1-adrenergic induction of the skeletal alpha-actin promoter during cardiac myocyte hypertrophy: transcriptional enhancer factor-1 and protein kinase C as conserved transducers of the fetal program in cardiac growth. J Biol Chem. 1995 ;270:410– 417.

72.

Molkentin JD, Dorn IG. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001 ;63:391– 426.

73.

Braz JC, Bueno OF, De Windt LJ, Molkentin JD. PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J Cell Biol. 2002 ;156:905– 919.

74.

Mochly-Rosen D. Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science. 1995 ;268:247– 251.

75.

Braun AP, Schulman H. The multifunctional calcium/calmodulin-dependent protein kinase: from form to function. Annu Rev Physiol. 1995 ;57:417– 445.

76.

Maier LS, Bers DM. Calcium, calmodulin, and calcium-calmodulin kinase II: heartbeat to heartbeat and beyond. J Mol Cell Cardiol. 2002;34:919– 939.

77.

Witcher DR, Kovacs RJ, Schulman H, Cefali DC, Jones LR. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem. 1991 ;266:11144– 11152.

78.

Davis BA, Schwartz A, Samaha FJ, Kranias EG. Regulation of cardiac sarcoplasmic reticulum calcium transport by calcium-calmodulin-dependent phosphorylation. J Biol Chem. 1983 ;258:13587– 13591.

79.

Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res. 1996 ;79:1059– 1063.

80.

Yuan W, Bers DM. Ca-dependent facilitation of cardiac Ca current is due to a Ca-calmodulin-dependent protein kinase. Am J Physiol. 1994;267:H982– H993.

81.

Xiao RP, Cheng H, Lederer WJ, Suzuki T, Lakatta EG. Dual regulation of Ca2+/calmodulin-dependent kinase II activity by membrane voltage and by calcium influx. Proc Natl Acad Sci U S A. 1994 ;91:9659– 9663.

82.

Anderson ME, Braun AP, Schulman H, Premack BA. Multifunctional Ca²⁺ calmodulin-dependent protein kinase mediates Ca²⁺-induced enhancement of the L-type Ca²⁺ current in rabbit ventricular myocytes. Circ Res. 1994 ;75:854– 861.

83.

Bassani RA, Mattiazzi A, Bers DM. CaMKII is responsible for activity-dependent acceleration of relaxation in rat ventricular myocytes. Am J Physiol. 1995 ;268:H703– H712.

84.

DeSantiago J, Maier LS, Bers DM. Frequency-dependent acceleration of relaxation in the heart depends on CaMKII, but not phospholamban. J Mol Cell Cardiol. 2002 ;34:975– 984.

85.

Wu Y, MacMillan LB, McNeill RB, Colbran RJ, Anderson ME. CaM kinase augments cardiac L-type Ca2+ current: a cellular mechanism for long Q-T arrhythmias. Am J Physiol. 1999 ;276:H2168– H2178.

86.

Wu Y, Roden DM, Anderson ME. Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res. 1999;84:906– 912.

87.

Hagemann D, Bohlender J, Hoch B, Krause EG, Karczewski P. Expression of Ca2+/calmodulin-dependent protein kinase II delta-subunit isoforms in rats with hypertensive cardiac hypertrophy. Mol Cell Biochem. 2001;220:69– 76.

88.

Currie S, Smith GL. Calcium/calmodulin-dependent protein kinase II activity is increased in sarcoplasmic reticulum from coronary artery ligated rabbit hearts. FEBS Lett. 1999 ;459:244– 248.

89.

Wu Y, Temple J, Zhang R, et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation. 2002 ;106:1288– 1293.

90.

Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983 ;245:C1– C14.

91.

Nabauer M, Callewaert G, Cleemann L, Morad M. Regulation of calcium release is gated by calcium current, not gating charge, in cardiac myocytes. Science. 1989;244:800– 803.

92.

Meyer M, Schillinger W, Pieske B, et al. Alterations in sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995 ;92:778– 784.

93.

Hasenfuss G, Reinecke H, Studer R, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res. 1994 ;75:434– 442.

94.

Marx SO, Reiken S, Hisamatsu Y, et al. Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine/isoleucine zippers. J Cell Biol. 2001 ;153:699– 708.

95.

Bandyopadhyay A, Shin DW, Ahn JO, Kim DH. Calcineurin regulates ryanodine receptor/Ca(2+)-release channels in rat heart. Biochem J. 2000;352:61– 70.

96.

Currie S, Loughrey CM, Craig MA, Smith GL. Calcium/calmodulin-dependent protein kinase II delta associates with the ryanodine receptor complex and regulates channel function in rabbit heart. Biochem J. 2004 ;377:357– 366.

97.

Hain J, Nath S, Mayrleitner M, Fleischer S, Schindler H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from skeletal muscle. Biophys J. 1994;67:1823– 1833.

98.

Herrmann-Frank A, Varsanyi M. Enhancement of Ca2+ release channel activity by phosphorylation of the skeletal muscle ryanodine receptor. FEBS Lett. 1993 ;332:237– 242.

99.

Sonnleitner A, Fleischer S, Schindler H. Gating of the skeletal calcium release channel by ATP is inhibited by protein phosphatase 1 but not by Mg2+. Cell Calcium. 1997 ;21:283– 290.

100.

Rodriguez P, Bhogal MS, Colyer J. Stoichiometric phosphorylation of cardiac ryanodine receptor on serine 2809 by calmodulin-dependent kinase II and protein kinase A. J Biol Chem. 2003 ;278:38593– 38600.

101.

Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000 ;101:365– 376.

102.

Marx SO, Marks AR. Regulation of the ryanodine receptor in heart failure. Basic Res Cardiol. 2002 ;97(suppl):I49– I51.

103.

Priori SO, Reiken S, Hisamatsu Y, et al. Mutations in the cardiac ryanodine receptor gene (hRYR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001 ;103:196– 200.

104.

Marks AR, Marx SO, Reiken S. Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers. Trends Cardiovasc Med. 2002 ;12:166– 170.

105.

Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003 ;113:829– 840.

106.

Marks AR. Ryanodine receptors, FKBP12, and heart failure. Front Biosci. 2002 ;7:970– 977.

107.

Reiken S, Gaburjakova M, Guatimosim S, et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts: role of phosphatases and response to isoproterenol. J Biol Chem. 2003 ;278:444– 453.

108.

Alam SQ, Ren YF, Alam BS. Effect of dietary trans fatty acids on some membrane-associated enzymes and receptors in rat heart. Lipids. 1989;24:39– 44.

109.

Morgado N, Galleguillos A, Sanhueza J, Garrido A, Nieto S, Valenzuela A. Effect of the degree of hydrogenation of dietary fish oil on the trans fatty acid content and enzymatic activity of rat hepatic microsomes. Lipids. 1998;33:669– 673.

110.

Rauch J, Gumperz J, Robinson C, et al. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem. 2003;278:47508– 47515.